Classifying PML risk with disease modifying therapies
- 1 February 2017
- journal article
- review article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 12, 59-63
- https://doi.org/10.1016/j.msard.2017.01.006
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assayJournal of NeuroVirology, 2016
- Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarateNeurology Neuroimmunology & Neuroinflammation, 2016
- Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosisJournal of the Neurological Sciences, 2015
- A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathyJournal of NeuroVirology, 2014
- JC virus antibody status underestimates infection ratesAnnals of Neurology, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2012
- Monoclonal antibodies and progressive multifocal leukoencephalopathymAbs, 2009
- Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen ConsequencesThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus InfectionAnnals of Internal Medicine, 1987
- Progressive Multifocal LeukoencephalopathyNeurologic Clinics, 1984